SEC Tracker
Get the app

Keros Therapeutics KROS

Keros Therapeutics updates corporate presentation

Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Routine
  1. Corporate presentation dated November 2026 attached as Exhibit 99.1.
  2. Presentation includes forward-looking statements about product candidates and clinical trials.
  3. Keros highlights potential of rinvatercept for neuromuscular diseases.
  4. Rinvatercept is designed to inhibit TGF-β ligands and improve muscle and bone health.

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Keros Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Zevra Therapeutics ZVRA public float $455M, Jun 30, 2025
  2. Theravance Biopharma TBPH public float $449M, Jun 30, 2025
  3. aTYR PHARMA ATYR public float $464M, Jun 30, 2025
  4. Arvinas ARVN public float $469M, Jun 30, 2025
  5. Arbutus Biopharma ABUS public float $472M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.